Ann: Volpara September Newsletter, page-38

lots of negative speculation here with no basis.. VHT has a huge growth market in US and here.. it is a valuable product in niche that needs it. It's still flying beneath the radar.. it will take off like a rocket as medical treatement restrictions ease...

Volpara Health Technologies Ltd (ASX: VHT)

Volpara uses artificial intelligence imaging algorithms to assist with the early detection of breast cancer. At the last count, its market share in the United States had grown to 27% of women screened for breast cancer. The company also advised that the annual revenue per user (ARPU) within its US breast cancer operations stood at approximately NZ$1.70 (US$1.09). However, thanks to the expansion of its product suite, during the second quarter the company has been seeing quotes with ARPU rising up to US$8.00. This is a huge step forward and validates management’s belief that its whole software platform will command ARPU of US$10.00.